SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regeneron shares surged after a strong third-quarter earnings report, with growth in Dupixent and Eylea HD cited as key drivers. Traders welcomed the beat and breakout, while debating whether the rally will hold and whether newer products can sustain growth.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to fresh 52-week highs has drawn attention as traders focus on BRIUMVIs sales growth and the upcoming Q3 update, with subcutaneous BRIUMVI data also viewed as a potential catalyst. Buyout and short-squeeze theories are circulating, but some traders argue the move reflects commercial momentum and earnings positioning rather than a confirmed deal.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A strong third-quarter earnings beat and higher full-year sales outlook, powered by demand for Mounjaro and Zepbound, are driving LLYs rally and bullish reactions. Traders also debate the stocks valuation and lower profit guidance tied to acquisition-related charges, while some point to Foundayos weaker-than-expected sales.

Lennar Corp. engages in the provision of real estate related financial and investment management services. It operates through the following segments: Homebuilding, Financial Services, Multifamily, and Lennar Other. The Homebuilding segment refers to the construction and sale of single-family attached and detached homes and the purchase, development, and sale of residential land directly and through entities. The Financial Services segment focuses on mortgage financing, title, and closing services for buyers. The Multifamily segment is involved in the development, construction, and property management of multifamily rental properties. The Lennar Other segment includes funds, asset management platform, and strategic investments in technology companies. The company was founded in 1954 and is headquartered in Miami, FL.

Lennar Corp. - Ordinary Shares - Class A

Lennar Corp.

Berkshire Hathaways reported accumulation of a sizable Lennar stake has drawn bullish attention, while Hunterbrooks short report alleging Lennar-related home sales to its Millrose spinoff has fueled concerns about circular transactions and earnings quality. Traders are weighing the value-investor signal against those allegations and ongoing pressure from high mortgage rates, weak affordability, and softer housing demand.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgen is drawing attention after positive Phase 3 updates for its cancer and Sjgrens disease programs, alongside a strong earnings report and new highs. Traders are broadly upbeat about the pipeline and momentum, though some are watching options positioning and questioning whether the rally has run too far ahead of upcoming catalysts.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileyes latest earnings have drawn attention as the stock sells off to a new 52-week low despite beating quarterly estimates and modestly raising its outlook. Bearish traders question growth, profitability, and its ability to win advanced-driving programs, while bulls point to its cash position and view the decline as overdone.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Reports of abrupt layoffs in India and the Philippines, attributed to a scaled-down business assignment, have fueled concern that Innodata may have lost or reduced a major client project. Traders disagree over whether the cuts signal weaker demand or a shift toward leaner operations; the company has not clarified the reason, and investors are looking to earnings for more detail.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs announcement that the REGAL Phase 3 AML trial reached its 80th event, triggering database lock and analysis ahead of topline results, dominates discussion. Traders are divided over whether GPS will improve survival enough to meet the trial endpoint, while the share-price decline after the milestone has fueled questions about the outlook and trial uncertainties.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

Northlands upgrade, tied to C3 Codes potential to speed development of agentic AI applications, is fueling interest in C3.ais turnaround prospects. Bullish traders point to options activity and high short interest as possible support for a rebound, while skeptics cite declining revenue and question whether the new product can translate into sustained growth.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002, and is headquartered in Cambridge, MA.

Alnylam Pharmaceuticals Inc

Shares are under pressure after Alnylams Q3 update, with traders focused on slower-than-expected Amvuttra demand growth, Medicare access concerns and delayed pipeline updates. Some investors point to strong product sales and the companys broader RNAi pipeline, while critics argue the growth outlook and management execution no longer support prior expectations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
